Sandbox fungal meningitis: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Automated text replacement (-Category:Primary care +))
 
(29 intermediate revisions by 2 users not shown)
Line 20: Line 20:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Liposomal amphotericin B]] 5 mg/kg/day for 4–6 weeks'''''  
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Liposomal amphotericin B]] 5 mg/kg/day IV for 4–6 weeks'''''  
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''Followed  By''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''Followed  By''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluconazole]] 800 mg/day''''' <BR>''OR''<BR>▸ '''''[[Itraconazole]] 200 mg bid or tid'''''<BR>''OR''<BR>▸ '''''[[Voriconazole]] 200–400 mg q12h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluconazole]] 800 mg/day PO''''' <BR>''OR''<BR>▸ '''''[[Itraconazole]] 200 mg PO bid or tid'''''<BR>''OR''<BR>▸ '''''[[Voriconazole]] 200–400 mg IV q12h'''''
|-
|-
|}
|}
Line 31: Line 31:


</div></div>
</div></div>
<div class="mw-collapsible mw-collapsed">
===Candidiasis===
<div class="mw-collapsible-content">
{|
|-
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Candidiasis]]}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[lipid-based ampho B]] 3–5 mg/kg/day'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS OR NOT''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ 5-Fluorocytosine]] 25 mg/kg PO qid'''''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluconazole]] 400–800 mg (6–12 mg/kg) IV or PO'''''
|-
|}
|}
</div></div>
<div class="mw-collapsible mw-collapsed">
===Histoplasma===
<div class="mw-collapsible-content">
{|
|-
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Histoplasma]]}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Liposomal ampho B]] 5 mg/kg/d, for a total of 175 mg/kg over  4-6 wk'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''Followed By''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Itraconazole]] 200 mg/day PO bid or tid for at least 12 month
|-
|}
|}
</div></div>
<div class="mw-collapsible mw-collapsed">
===Coccidioides<ref name="pmid16206093">Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA et al. (2005) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16206093 Coccidioidomycosis.] ''Clin Infect Dis'' 41 (9):1217-23. [http://dx.doi.org/10.1086/496991 DOI:10.1086/496991] PMID: [http://pubmed.gov/16206093 16206093]</ref>===
<div class="mw-collapsible-content">
{|
|-
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Coccidioides]]}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[FLuconazole]] 400 mg/day PO'''''<BR>''OR''<BR>▸ '''''[[Itraconazole]] 400–600 mg/day PO'''''
|-
|}
|}
</div></div>
<div class="mw-collapsible mw-collapsed">
===Cryptococcus HIV/AIDS<ref name="pmid24052889">Antinori S (2013) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=24052889 New Insights into HIV/AIDS-Associated Cryptococcosis.] ''ISRN AIDS'' 2013 ():471363.http://dx.doi.org/10.1155/2013/471363 DOI:10.1155/2013/471363] PMID: [http://pubmed.gov/24052889 24052889]</ref>===
<div class="mw-collapsible-content">
{|
|-
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Cryptococcus, HIV/AIDS]]}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Induction Phrase(for 2 wks)''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amphotericin B deoxycholate]] 0.7 mg/kg/day IV'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[5-Fluorocytosine]] 100 mg/kg/day PO'''''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Consolidation phase(for 8 wks)''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluconazole]] 400 mg/day PO'''''<BR>''OR''<BR>▸ '''''[[Itraconazole]] 400 mg/day PO'''''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Maintenance phase''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluconazole]] 200 mg/day PO'''''
|-
|}
|}
</div></div>
<div class="mw-collapsible mw-collapsed">
===Cryptococcus Immunocompetent<ref name="pmid22763808">Jackson A, van der Horst C (2012) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=22763808 New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis.] ''Curr HIV/AIDS Rep'' 9 (3):267-77. [http://dx.doi.org/10.1007/s11904-012-0127-7 DOI:10.1007/s11904-012-0127-7] PMID: [http://pubmed.gov/22763808 22763808]</ref>===
<div class="mw-collapsible-content">
{|
|-
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Cryptococcus, Immunocompetent]]}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Induction Phrase(for 2 wks)''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amphotericin B]] 0.7-1 mg/kg/day IV'''''<BR>''OR''<BR>▸ '''''[[Liposomal amphotericin B]] 5 mg/kg/day PO
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[5-Fluorocytosine]] 25 mg/kg  PO q6h'''''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Consolidation phase(for 8 wks)''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluconazole]] 400 mg/day PO qd'''''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Maintenance phase(for 12 mo)''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluconazole]] 200 mg PO qd'''''
|-
|}
|}
</div></div>
==Viral Meningitis<ref name="pmid23377760">Studahl M, Lindquist L, Eriksson BM, Günther G, Bengner M, Franzen-Röhl E et al. (2013) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=23377760 Acute viral infections of the central nervous system in immunocompetent adults: diagnosis and management.] ''Drugs'' 73 (2):131-58. [http://dx.doi.org/10.1007/s40265-013-0007-5 DOI:10.1007/s40265-013-0007-5] PMID: [http://pubmed.gov/23377760 23377760]</ref>==
{|
|-
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Herpes simplex Meningitis]]}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aciclovir]]''''' IV  <BR>''OR''<BR>▸ '''''[[Valaciclovir]]''''' PO
|-
|}
|}
==Parasitic Meningitis==
===Angiostrongyliasis===
{|
|-
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Angiostrongyliasis]]}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[albendazole]] 60 kg or greater: 400 mg twice daily PO with
meals<BR>''OR''<BR> less than 60 kg:7.5 mg/kg PO bid with meals (maximum total daily dose 800 mg)'''''
|-
|}
|}
===Amebic meningoencephalitis===
{|
|-
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Amebic meningoencephalitis]]}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Miltefosine]]'''''
|-
|}
|}
===Eosinophilic myeloencephalitis, Meningitis===
{|
|-
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Eosinophilic myeloencephalitis, Meningitis]]}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[albendazole]]'''''
|-
|}
|}
===Toxoplasma gondii, Meningitis===
{|
|-
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Toxoplasma gondii, Meningitis]]}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[albendazole]]'''''
|-
|}
|}
==M. tuberculosis Meningitis <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from Treatment of Tuberculosis guidelines<ref>{{Cite web  | last =  | first =  | title = http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf?ua=1 | url = http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf?ua=1 | publisher =  | date =  | accessdate = 22 January 2014 }}</ref></SMALL></SMALL></SMALL></SMALL></SMALL>==
{|
|-
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[M. tuberculosis]]}}''
|-! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Intensive Phase(for 9-12 mo)''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 8-12 mg/kg/day PO daily max: 600mg<BR> ''OR''<BR> 8-12mg/kg/day PO 3 times per week x:600mg'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Isoniazid]] 4-6 mg/kg/day PO daily max: 300mg<BR>''OR''<BR> 8-12mg/kg/day PO 3 times per week daily max:900mg'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Pyrazinamide]] 20-30 mg/kg/day PO<BR>''OR''<BR> 30-40mg/kg/day PO 3 times per week'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Streptomycin]] 12-18 mg/kg/day IM<BR>''OR''<BR> 25-35mg/kg/day PO 3 times per week daily max:1000mg'''''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Continuation Phase''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 8-12 mg/kg/day PO daily max: 600mg<BR>''OR''<BR> 8-12mg/kg/day PO 3 times per week daily max:600mg'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Isoniazid]] 4-6 mg/kg/day PO daily max: 300mg<BR>''OR''<BR> 8-12mg/kg/day PO 3 times per week daily max:900mg'''''
|-
|}
|}
==References==
{{reflist|2}}
[[Category:Needs overview]]
[[Category:Disease]]
[[Category:Neurology]]
[[Category:Emergency medicine]]
[[Category:Diseases involving the fasciae]]
[[Category:Inflammations]]
[[Category:Neurological disorders]]

Latest revision as of 06:37, 28 July 2020

Meningitis Main Page

Patient Information

Overview

Causes

Classification

Viral Meningitis
Bacterial Meningitis
Fungal Meningitis

Differential Diagnosis

Diagnosis

Treatment

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Sheng Shi, M.D. [2]


fungal meningitis

Blastomyces

Blastomyces
Preferred Regimen
Liposomal amphotericin B 5 mg/kg/day IV for 4–6 weeks
Followed By
Fluconazole 800 mg/day PO
OR
Itraconazole 200 mg PO bid or tid
OR
Voriconazole 200–400 mg IV q12h


Candidiasis

Candidiasis
Preferred Regimen
lipid-based ampho B 3–5 mg/kg/day
PLUS OR NOT
5-Fluorocytosine 25 mg/kg PO qid
Alternative Regimen
Fluconazole 400–800 mg (6–12 mg/kg) IV or PO


Histoplasma

Histoplasma
Preferred Regimen
Liposomal ampho B 5 mg/kg/d, for a total of 175 mg/kg over 4-6 wk
Followed By
Itraconazole 200 mg/day PO bid or tid for at least 12 month


Coccidioides[1]

Coccidioides
Preferred Regimen
FLuconazole 400 mg/day PO
OR
Itraconazole 400–600 mg/day PO


Cryptococcus HIV/AIDS[2]

Cryptococcus, HIV/AIDS
Induction Phrase(for 2 wks)
Amphotericin B deoxycholate 0.7 mg/kg/day IV
PLUS
5-Fluorocytosine 100 mg/kg/day PO
Consolidation phase(for 8 wks)
Fluconazole 400 mg/day PO
OR
Itraconazole 400 mg/day PO
Maintenance phase
Fluconazole 200 mg/day PO


Cryptococcus Immunocompetent[3]

Cryptococcus, Immunocompetent
Induction Phrase(for 2 wks)
Amphotericin B 0.7-1 mg/kg/day IV
OR
Liposomal amphotericin B 5 mg/kg/day PO
PLUS
5-Fluorocytosine 25 mg/kg PO q6h
Consolidation phase(for 8 wks)
Fluconazole 400 mg/day PO qd
Maintenance phase(for 12 mo)
Fluconazole 200 mg PO qd



Viral Meningitis[4]

Herpes simplex Meningitis
Preferred Regimen
Aciclovir IV
OR
Valaciclovir PO


Parasitic Meningitis

Angiostrongyliasis

Angiostrongyliasis
Preferred Regimen
albendazole 60 kg or greater: 400 mg twice daily PO with

meals
OR
less than 60 kg:7.5 mg/kg PO bid with meals (maximum total daily dose 800 mg)

Amebic meningoencephalitis

Amebic meningoencephalitis
Preferred Regimen
Miltefosine

Eosinophilic myeloencephalitis, Meningitis

Eosinophilic myeloencephalitis, Meningitis
Preferred Regimen
albendazole


Toxoplasma gondii, Meningitis

Toxoplasma gondii, Meningitis
Preferred Regimen
albendazole

M. tuberculosis Meningitis Adapted from Treatment of Tuberculosis guidelines[5]

M. tuberculosis
Rifampicin 8-12 mg/kg/day PO daily max: 600mg
OR
8-12mg/kg/day PO 3 times per week x:600mg
PLUS
Isoniazid 4-6 mg/kg/day PO daily max: 300mg
OR
8-12mg/kg/day PO 3 times per week daily max:900mg
PLUS
Pyrazinamide 20-30 mg/kg/day PO
OR
30-40mg/kg/day PO 3 times per week
PLUS
Streptomycin 12-18 mg/kg/day IM
OR
25-35mg/kg/day PO 3 times per week daily max:1000mg
Continuation Phase
Rifampicin 8-12 mg/kg/day PO daily max: 600mg
OR
8-12mg/kg/day PO 3 times per week daily max:600mg
PLUS
Isoniazid 4-6 mg/kg/day PO daily max: 300mg
OR
8-12mg/kg/day PO 3 times per week daily max:900mg

References

  1. Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA et al. (2005) Coccidioidomycosis. Clin Infect Dis 41 (9):1217-23. DOI:10.1086/496991 PMID: 16206093
  2. Antinori S (2013) New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS 2013 ():471363.http://dx.doi.org/10.1155/2013/471363 DOI:10.1155/2013/471363] PMID: 24052889
  3. Jackson A, van der Horst C (2012) New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis. Curr HIV/AIDS Rep 9 (3):267-77. DOI:10.1007/s11904-012-0127-7 PMID: 22763808
  4. Studahl M, Lindquist L, Eriksson BM, Günther G, Bengner M, Franzen-Röhl E et al. (2013) Acute viral infections of the central nervous system in immunocompetent adults: diagnosis and management. Drugs 73 (2):131-58. DOI:10.1007/s40265-013-0007-5 PMID: 23377760
  5. "http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf?ua=1" (PDF). Retrieved 22 January 2014. External link in |title= (help)